Áttétes emlőrák: vizsgálatok itt: Spanyolország
74 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 1/2. fázisTaking peopleA Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- Where
- Barcelona, Madrid, Pamplona, Pozuelo de Alarcón
- Életkor
- 18 év and over
- People
- 380 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06827236 · EU 2024-517979-20-00 - 1. fázisTaking peopleA Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- Where
- Logrono, Madrid, Valencia
- Életkor
- 18 év and over
- People
- 150 worldwide
- Run by
- IDEAYA Biosciences
See details and how to joinNCT07503808 · EU 2026-526299-21-00 - 2. fázisTaking peopleASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Where
- Barcelona, Bilbao, Lleida, Madrid, Málaga, Seville
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- ALX Oncology Inc.
See details and how to joinNCT07007559 - 3. fázisTaking peopleBGB-43395 in Combination with Letrozole versus CDK4/6i with Letrozole for Patients with Previously Untreated Advanced or Metastatic HR+/HER2- Breast Cancer
- Where
- Badajoz, Barcelona, Donostia, Elche, Granada, Madrid, Santiago de Compostela, Sevilla
- Életkor
- 18 év and over
- People
- 233 worldwide
- Run by
- BeOne Medicines I GmbH
See details and how to joinNCT07492641 · EU 2025-523960-19-00 - 1/2. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Where
- Barcelona, Madrid, Sevilla
- Életkor
- 18 év and over
- People
- 1132 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT03424005 · EU 2023-503629-20-00 - 1/2. fázisTaking peopleBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Where
- A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Seville, Valencia
- Életkor
- 18 év and over
- People
- 910 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06324357 - 3. fázisTaking peoplePhase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Where
- Badajoz, Badalona, Barcelona, Cáceres, Castello De La Plana, Girona, Huelva, Jaén, L'Hospitalet de Llobregat, Lleida, Madrid, Murcia, Palma, Pamplona, San Cristóbal de La Laguna, Sant Cugat del Vallès, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 540 worldwide
- Run by
- Relay Therapeutics, Inc.
See details and how to joinNCT06982521 · EU 2025-523083-21-00 - 1. fázisTaking peopleA Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
- Where
- Barcelona, Madrid, Valencia
- Életkor
- 18 év and over
- People
- 260 worldwide
- Run by
- Pfizer
See details and how to joinNCT07318805 · EU 2025-524387-38-00 - 2/3. fázisTaking peopleRO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
- Where
- Barcelona, Bilbao, EL Palmar (EL Palmar), Granada, Jaén, Madrid, Málaga, San Cristóbal de La Laguna, Seville, Valencia
- Életkor
- 18 év and over
- People
- 650 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07413939 · EU 2025-524498-17-00 - 3. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Where
- Barcelona, Bilbao, Elche, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 450 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06790693 · EU 2024-516162-11-00 - 3. fázisTaking peopleA Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Where
- Badajoz, Barcelona, Cáceres, Donostia / San Sebastian, Granada, Hospitalet, Jaén, Las Palmas de Gran Canaria, Lleida, Madrid, Málaga, Palma, Salamanca, San Cristóbal de La Laguna, Santiago de Compostela, Seville, Valencia, Zaragoza
- Életkor
- 18 év and over
- People
- 800 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07174336 · EU 2025-522791-92-00 - 3. fázisTaking peopleA Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Where
- A Coruña, Badalona, Barcelona, Madrid, Santander, Seville
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07060807 · EU 2025-520582-51-00 - 2. fázisTaking peopleTo Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
- Where
- Barcelona, Granada, Madrid, Valencia
- Életkor
- 18 év and over
- People
- 80 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07368998 · EU 2025-522805-39-00 - 2. fázisTaking peopleA Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
- Where
- Barcelona, Granada, L'Hospitalet de Llobregat, Madrid, Valencia
- Életkor
- 18 év and over
- People
- 80 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07405801 · EU 2025-523013-28-00 - 1. fázisTaking peopleStudy of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
- Where
- Madrid
- Életkor
- 18 év and over
- People
- 194 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07604571 - 1/2. fázisTaking peopleTreatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS
- Where
- Barcelona, Madrid, Pamplona
- Életkor
- 18 év and over
- People
- 20
- Run by
- Fundacio Clinic Barcelona
See details and how to joinNCT05451784 · EU 2024-511915-21-01 - 3. fázisTaking peopleA Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment (EmpowHER 303)
- Where
- A Coruña, Alicante, Badajoz, Badalona, Barcelona, Elche, Granada, Lleida, Madrid, Palma, San Cristóbal de La Laguna, Santiago de Compostela, Sevilla, Valencia, Vigo
- Életkor
- 18 év and over
- People
- 264 worldwide
- Run by
- Jazz Pharmaceuticals Ireland Limited
See details and how to joinNCT06435429 · EU 2023-508960-31-00 - 3. fázisTaking peopleSaruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- Where
- Barcelona, Cáceres, Granada, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 788 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06380751 · EU 2023-504180-16-00 - 3. fázisTaking peopleEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Where
- Barcelona, Córdoba, Madrid, Málaga, Pamplona, Valencia
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- LeonaBio
See details and how to joinNCT05696626 · EU 2023-503708-10-00 - 3. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
- Where
- Barcelona, Cáceres, L'Hospitalet de Llobregat, Madrid, Málaga, Murcia, San Cristobal De La Laguna, Santiago de Compostela, Sevilla
- Életkor
- 18 év and over
- People
- 420 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05646862 · EU 2022-502322-41-00 - 1/2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Sevilla
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - 1. fázisNot yet taking people in SpanyolországA phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid
- Életkor
- 18 év and over
- People
- 64 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-518348-19-00 · EU 2024-518348-19-00 - 1. fázisTaking peopleA clinical trial to learn about the effects of IEV407 when given alone or with endocrine therapy in people with advanced breast cancer
- Where
- Madrid, Valencia
- Életkor
- 18 év and over
- People
- 40 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-522707-26-00 · EU 2025-522707-26-00 - 1/2. fázisNot yet taking people in SpanyolországA Phase I First-in-Human Dose Escalation Trial to Evaluate the Safety and Efficacy of ARI-HER2 (HER2BBz CAR-T Cells) in Patients with HER2Positive Advanced Breast Cancer
- Where
- Barcelona, Madrid, Pamplona
- Életkor
- 18 év to 64 év
- People
- 18
- Run by
- Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
See details and how to join2026-527365-30-00 · EU 2026-527365-30-00 - 2. fázisTaking peopleEvaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
- Where
- L'Hospitalet de Llobregat, Madrid
- Életkor
- 18 év and over
- People
- 90 worldwide
- Run by
- Delcath Systems Inc.
See details and how to joinNCT06875128 · EU 2025-521966-91-00